The difference between dacomitinib and afatinib in effectiveness and safety in first-line treatment of patients with advanced EGFR-mutant non-small cell lung cancer: a real-world observational study

被引：0
|
作者：
Wen-Chien Cheng
Chi-Chien Lin
Wei-Chih Liao
Yu-Chao Lin
Chia-Hung Chen
Hung-Jen Chen
Chih-Yen Tu
Te-Chun Hsia
机构：
[1] China Medical University Hospital,Division of Pulmonary and Critical Care, Department of Internal Medicine
[2] China Medical University,School of Medicine, College of Medicine
[3] National Chung Hsing University,Department of Life Science
[4] National Chung Hsing University,PhD Program in Translational Medicine
[5] National Chung Hsing University,Rong Hsing Research Center for Translational Medicine
[6] National Chung-Hsing University,Institute of Biomedical Science, the iEGG and Animal Biotechnology Center, Advanced Plant and Food Crop Biotechnology Center
[7] Kaohsiung Medical University,Department of Pharmacology, College of Medicine
[8] Taichung Veterans General Hospital,Department of Medical Research
来源：
BMC Cancer | / 24卷
关键词：
Non-small cell lung cancer (NSCLC); Epidermal growth factor receptor (EGFR); Dacomitinib; Afatinib;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [41] Real-world analysis of afatinib as a first-line treatment for patients with advanced stage non-small-cell lung cancer with uncommon EGFR mutations: a multicenter study in Vietnam
    Pham, Van Luan
    Le, Tuan Anh
    Pham, Cam Phuong
    Nguyen, Thi Thai Hoa
    Do, Anh Tu
    Nguyen, Tuan Khoi
    Nguyen, Minh Hai
    Hoang, Thi Anh Thu
    Vuong, Dinh Thy Hao
    Nguyen, Dac Nhan Tam
    Dang, Van Khiem
    Nguyen, Thi Oanh
    Vo, Thi Huyen Trang
    Do, Hung Kien
    Vu, Ha Thanh
    Nguyen, Thi Thuy Hang
    Pham, Van Thai
    Trinh, Le Huy
    Nguyen, Khac Dung
    Nguyen, Hoang Gia
    Truong, Cong Minh
    Pham, Tran Minh Chau
    Nguyen, Thi Bich Phuong
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2024, 16
  • [42] Real-World Study of Patients With EGFR Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer Treated With First-Line Osimertinib
    Nieva, J.
    Taylor, A.
    Servidio, L.
    Sun, P.
    Okhuoya, P.
    Horvat, P.
    Tolani, E.
    Magee, K.
    Mathur, R.
    Balakrishna, S.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (10) : S1113 - S1113
  • [43] Comparative analysis of first-line treatment regimens for advanced EGFR-mutant non-small cell lung cancer patients with stable brain metastases
    Dai, Lu
    Luo, Chun-Yue
    Hu, Guang-Xia
    Chen, Gang
    Wu, Chuan-Xin
    Yin, Jun
    Jiang, Ze-Yong
    Hu, Guang-Fu
    Zhao, Jian
    Fu, Wen-Fan
    ANNALS OF PALLIATIVE MEDICINE, 2020, 9 (04) : 2062 - +
  • [44] Real-world management patterns in EGFR-mutant advanced non-small-cell lung cancer before first-line adoption of osimertinib: the REFLECT study in Greece
    Lampaki, Sofia
    Mountzios, Giannis
    Georgoulias, Vassilis
    Rapti, Aggeliki
    Xanthakis, Ioannis
    Baka, Sofia
    Mavroudis, Dimitrios
    Samantas, Epaminondas
    Athanasiadis, Elias
    Zagouri, Flora
    Charpidou, Andriani
    Somarakis, Alvertos
    Papista, Christina
    Nikolaou, Aristeidis
    Anastasopoulou, Eleftheria
    Paparepa, Zoe
    Syrigos, Konstantinos N.
    FUTURE ONCOLOGY, 2022, 18 (28) : 3151 - 3164
  • [45] Does dose reduction of afatinib affect treatment outcomes of patients with EGFR-mutant metastatic non-small cell lung cancer in real-world clinical practice?
    Poh, Mau Ern
    Chai, Chee Shee
    Liam, Chong Kin
    Ho, Gwo Fuang
    Pang, Yong Kek
    Hasbullah, Harissa Husainy
    Tho, Lye Mun
    Nor, Ibtisam Muhamad
    Ho, Kean Fatt
    Thiagarajan, Muthukkumaran
    Samsudin, Azlina
    Omar, Azza
    Ong, Choo Khoon
    Soon, Sing Yang
    Tan, Sin Nee
    How, Soon Hin
    TRANSLATIONAL LUNG CANCER RESEARCH, 2024, 13 (02) : 307 - 320
  • [46] Safety and Efficacy of First-Line Dacomitinib in Advanced Non-Small Cell Lung Cancer by EGFR Mutation SUBtype in ARCHER 1050
    Pluzanski, A.
    Wu, Y.
    Cheng, Y.
    Zhou, X.
    Migliorino, M. R.
    Niho, S.
    Nakagawa, K.
    Lee, K. H.
    Corral, J.
    Rosell, R.
    Linke, R.
    Tang, Y.
    Pastel, M.
    Wilner, K.
    Mok, T.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (03) : S617 - S618
  • [47] Efficacy and prognostic factors of first-line afatinib treatment for the EGFR-mutated non-small cell lung cancer in the real world
    Chiu, Tzu Hsuan
    Huang, Chi-Hsien
    Kuo, Chih-Hsi Scott
    EUROPEAN RESPIRATORY JOURNAL, 2020, 56
  • [48] Dacomitinib as first-line treatment for EGFR mutation-positive non-small cell lung cancer
    Reungwetwattana, Thanyanan
    Rohatgi, Nitesh
    Mok, Tony S.
    Prabhash, Kumar
    EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT, 2021, 6 (03): : 161 - 171
  • [49] Real-world analysis of the effect of gefitinib as a first-line therapy in patients with advanced non-small cell lung cancer with EGFR mutations
    Pham Van Luan
    Nguyen Dinh Tien
    Nguyen Minh Hai
    Nguyen Dao Tien
    Thi Thi Duyen
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2021, 13
  • [50] A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice
    Liu, Yanxia
    Gao, Yuan
    Wang, Ying
    Zhao, Cong
    Zhang, Zhiyun
    Li, Baolan
    Zhang, Tongmei
    BMC CANCER, 2022, 22 (01)
12345